Compare Progressive Corp (PGR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs ResMed Inc. — how do they compare? Progressive Corp trades at $218.9 (market cap $126.95B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: Progressive Corp is far larger — about 4× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and ResMed Inc. for 51 Days on average.
| PGR | RMD | |
|---|---|---|
Market Cap | $126.95B | $31.89B |
Volume | 2,749,438 | 618,314 |
Sector | Financials | Health |
52-Week High | $242.16 | $277.88 |
52-Week Low | $190.40 | $182.82 |
Typical Hold Time | 81 Days | 51 Days |
Enterprise Value | $135.16B | $31.24B |
Dividend Yield | 0.18% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook. The stock shows strong fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Valuation metrics appear reasonable with P/E of 10.74 and ROE of 34.94%. Recent earnings beat expectations in Q2 2026, and analyst consensus targets $222.23.
PGR presents a compelling investment case with consistent revenue growth and strong profitability. However, investors face risks from intensifying auto insurance competition and potential margin pressure. The stock's current price near resistance levels suggests limited near-term upside despite positive analyst sentiment.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
